‘The Boys' Star Erin Moriarty Shares Graves' Disease Diagnosis
The Boys star Erin Moriarty shared she was recently diagnosed with Graves' disease, advocating for people to listen to their bodies, especially when in pain.
'Autoimmune disease manifests differently in everybody/every body,' she wrote in an Instagram post. 'Your experience will be different from mine. My experience will be different from yours. Perhaps greatly, perhaps minutely.'
More from Deadline
Chace Crawford Had To Break Out Of "CW Pretty Boy Jail" After 'Gossip Girl'
Jaz Sinclair Accepts Monte-Carlo TV Festival Award, Teases Darker Tone For Season 2 Of Prime Video's 'Gen V'
It Starts On The Page (Drama): Read 'The Boys' Season 4 Finale Script With Foreword By Eric Kripke, Jessica Chou & David Reed
Per the Cleveland Clinic, the autoimmune disorder affects the thyroid gland, resulting in the overproduction of the thyroid hormone, also known as hyperthyroidism, the most common cause of which is Graves' disease. A very common illness, it's most prevalent among women and people younger than 40, with wide-ranging symptoms that can include heat sensitivity, weight loss, tremors, irregular heartbeat and potentially Graves' ophthalmopathy, which develops in 1 out of 3 people with Graves' disease and includes eye issues like bulging eyes, light sensitivity and eye pressure or irritation. Untreated Graves' disease can lead to heart problems and osteoporosis, and treatments include medication like beta-blockers and antithyroid agents, as well as radioiodine therapy and surgery.
'One thing I can say: if I hadn't chalked it all up to stress and fatigue, I would've caught this sooner,' she added. 'A month ago, I was diagnosed with Graves' disease. Within 24 hours of beginning treatment, I felt the light coming back on. It's been increasing in strength ever since. If yours is dimming, even slightly, go get checked. Don't 'suck it up' and transcend suffering; you deserve to be comfy. Sh–'s hard enough as is.'
Interspersed with the images of the actress were screenshots of texts sent to her parents: one seemingly prior to her diagnosis sent to her mom and the other presumably after treatment had begun sent to her dad. The former read: 'I'm serious; I really really need relief. I feel nauseated tonight. I feel so sh– and removed from who I am, I can't live like this forever. Or that long. There aren't moments anymore, not even a passing 5 seconds, when I feel normal. I've never had that. Not one. It's not just fatigue – it's an ineffable, system wide cry for help and I don't know how long I can remain in this state.' In the latter, she wrote, 'I already feel a world of a difference, primary thought (as of now): 'damn, this is how I'm supposed to feel? I've been missing out!''
In the comments, industry peers shared supportive emojis, including The Boys' costar Susan Heyward and See actress Nesta Cooper. The Boys director Shana Stein wrote, 'So happy you're on the road to healing.'
Largely known for her work on Prime Video's The Boys, Moriarty portrays supe Starlight/Annie January, who leaves the Seven to join the cause against the megalomaniacal Homelander (Antony Starr). While there's no official release date for the fifth and final season of the Eric Kripke-created satire, due to be released next year, the cast teased a 'climactic end' to Deadline at a recent FYC panel.
Best of Deadline
2025 TV Series Renewals: Photo Gallery
2025 TV Cancellations: Photo Gallery
2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Cardinal Health Insiders Sell US$18m Of Stock, Possibly Signalling Caution
In the last year, many Cardinal Health, Inc. (NYSE:CAH) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The CEO & Director, Jason Hollar, made the biggest insider sale in the last 12 months. That single transaction was for US$8.0m worth of shares at a price of US$109 each. That means that an insider was selling shares at slightly below the current price (US$161). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 46% of Jason Hollar's holding. Cardinal Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! View our latest analysis for Cardinal Health I will like Cardinal Health better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying. Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Cardinal Health insiders own about US$146m worth of shares (which is 0.4% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. The fact that there have been no Cardinal Health insider transactions recently certainly doesn't bother us. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Cardinal Health insiders selling. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we found 1 warning sign for Cardinal Health that deserve your attention before buying any shares. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Why HCA Healthcare, Inc. (NYSE:HCA) Could Be Worth Watching
Today we're going to take a look at the well-established HCA Healthcare, Inc. (NYSE:HCA). The company's stock saw a decent share price growth of 19% on the NYSE over the last few months. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, could the stock still be trading at a relatively cheap price? Let's examine HCA Healthcare's valuation and outlook in more detail to determine if there's still a bargain opportunity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Good news, investors! HCA Healthcare is still a bargain right now according to our price multiple model, which compares the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that HCA Healthcare's ratio of 15.45x is below its peer average of 20.5x, which indicates the stock is trading at a lower price compared to the Healthcare industry. Although, there may be another chance to buy again in the future. This is because HCA Healthcare's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. See our latest analysis for HCA Healthcare Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. HCA Healthcare's earnings over the next few years are expected to increase by 23%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? Since HCA is currently below the industry PE ratio, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current price multiple. Are you a potential investor? If you've been keeping an eye on HCA for a while, now might be the time to make a leap. Its buoyant future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy HCA. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Our analysis shows 3 warning signs for HCA Healthcare (1 is a bit concerning!) and we strongly recommend you look at these before investing. If you are no longer interested in HCA Healthcare, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
How do painkillers actually kill pain? From ibuprofen to fentanyl, it's about meeting the pain where it's at
Without the ability to feel pain, life is more dangerous. To avoid injury, pain tells us to use a hammer more gently, wait for the soup to cool or put on gloves in a snowball fight. Those with rare inherited disorders that leave them without the ability to feel pain are unable to protect themselves from environmental threats, leading to broken bones, damaged skin, infections and ultimately a shorter life span. In these contexts, pain is much more than a sensation: It is a protective call to action. But pain that is too intense or long-lasting can be debilitating. So how does modern medicine soften the call? As a neurobiologist and an anesthesiologist who study pain, this is a question we and other researchers have tried to answer. Science's understanding of how the body senses tissue damage and perceives it as pain has progressed tremendously over the past several years. It has become clear that there are multiple pathways that signal tissue damage to the brain and sound the pain alarm bell. Interestingly, while the brain uses different pain signaling pathways depending on the type of damage, there is also redundancy to these pathways. Even more intriguing, these neural pathways morph and amplify signals in the case of chronic pain and pain caused by conditions affecting nerves themselves, even though the protective function of pain is no longer needed. Painkillers work by tackling different parts of these pathways. Not every painkiller works for every type of pain, however. Because of the multitude and redundancy of pain pathways, a perfect painkiller is elusive. But in the meantime, understanding how existing painkillers work helps medical providers and patients use them for the best results. A bruise, sprain or broken bone from an injury all lead to tissue inflammation, an immune response that can lead to swelling and redness as the body tries to heal. Specialized nerve cells in the area of the injury called nociceptors sense the inflammatory chemicals the body produces and send pain signals to the brain. Common over-the-counter anti-inflammatory painkillers work by decreasing inflammation in the injured area. These are particularly useful for musculoskeletal injuries or other pain problems caused by inflammation such as arthritis. Nonsteroidal anti-inflammatories like ibuprofen (Advil, Motrin), naproxen (Aleve) and aspirin do this by blocking an enzyme called COX that plays a key role in a biochemical cascade that produces inflammatory chemicals. Blocking the cascade decreases the amount of inflammatory chemicals, and thereby reduces the pain signals sent to the brain. While acetaminophen (Tylenol), also known as paracetamol, doesn't reduce inflammation as NSAIDs do, it also inhibits COX enzymes and has similar pain-reducing effects. Prescription anti-inflammatory painkillers include other COX inhibitors, corticosteroids and, more recently, drugs that target and inactivate the inflammatory chemicals themselves. Because inflammatory chemicals are involved in other important physiological functions beyond just sounding the pain alarm, medications that block them will have side effects and potential health risks, including irritating the stomach lining and affecting kidney function. Over-the-counter medications are generally safe if the directions on the bottle are followed strictly. Corticosteroids like prednisone block the inflammatory cascade early on in the process, which is probably why they are so potent in reducing inflammation. However, because all the chemicals in the cascade are present in nearly every organ system, long-term use of steroids can pose many health risks that need to be discussed with a physician before starting a treatment plan. Many topical medications target nociceptors, the specialized nerves that detect tissue damage. Local anesthetics, like lidocaine, prevent these nerves from sending electrical signals to the brain. The protein sensors on the tips of other sensory neurons in the skin are also targets for topical painkillers. Activating these proteins can elicit particular sensations that can lessen the pain by reducing the activity of the damage-sensing nerves, like the cooling sensation of menthol or the burning sensation of capsaicin. Because these topical medications work on the tiny nerves in the skin, they are best used for pain directly affecting the skin. For example, a shingles infection can damage the nerves in the skin, causing them to become overactive and send persistent pain signals to the brain. Silencing those nerves with topical lidocaine or an overwhelming dose of capsaicin can reduce these pain signals. Nerve injuries, most commonly from arthritis and diabetes, can cause the pain-sensing part of the nervous system to become overactive. These injuries sound the pain alarm even in the absence of tissue damage. The best painkillers in these conditions are those that dampen that alarm. Antiepileptic drugs, such as gabapentin (Neurontin), suppress the pain-sensing system by blocking electrical signaling in the nerves. However, gabapentin can also reduce nerve activity in other parts of the nervous system, potentially leading to sleepiness and confusion. Antidepressants, such as duloxetine and nortriptyline, are thought to work by increasing certain neurotransmitters in the spinal cord and brain involved in regulating pain pathways. But they may also alter chemical signaling in the gastrointestinal tract, leading to an upset stomach. All these medications are prescribed by doctors. Opioids are chemicals found or derived from the opium poppy. One of the earliest opioids, morphine, was purified in the 1800s. Since then, medical use of opioids has expanded to include many natural and synthetic derivatives of morphine with varying potency and duration. Some common examples include codeine, tramadol, hydrocodone, oxycodone, buprenorphine and fentanyl. Opioids decrease pain by activating the body's endorphin system. Endorphins are a type of opioid your body naturally produces that decreases incoming signals of injury and produces feelings of euphoria – the so-called 'runner's high.' Opioids simulate the effects of endorphins by acting on similar targets in the body. Although opioids can decrease some types of acute pain, such as after surgery, musculoskeletal injuries like a broken leg or cancer pain, they are often ineffective for neuropathic injuries and chronic pain. Because the body uses opioid receptors in other organ systems like the gastrointestinal tract and the lungs, side effects and risks include constipation and potentially fatal suppression of breathing. Prolonged use of opioids may also lead to tolerance, where more drug is required to get the same painkilling effect. This is why opioids can be addictive and are not intended for long-term use. All opioids are controlled substances and are carefully prescribed by doctors because of these side effects and risks. Although cannabis has received a lot of attention for its potential medical uses, there isn't sufficient evidence available to conclude that it can effectively treat pain. Since the use of cannabis is illegal at the federal level in the U.S., high-quality clinical research funded by the federal government has been lacking. Researchers do know that the body naturally produces endocannabinoids, a form of the chemicals in cannabis, to decrease pain perception. Cannabinoids may also reduce inflammation. Given the lack of strong clinical evidence, physicians typically don't recommend them over FDA-approved medications. While sounding the pain alarm is important for survival, dampening the klaxon when it's too loud or unhelpful is sometimes necessary. No existing medication can perfectly treat pain. Matching specific types of pain to drugs that target specific pathways can improve pain relief, but even then, medications can fail to work even for people with the same condition. More research that deepens the medical field's understanding of the pain pathways and targets in the body can help lead to more effective treatments and improved pain management. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Rebecca Seal, University of Pittsburgh and Benedict Alter, University of Pittsburgh Read more: How do drugs know where to go in the body? A pharmaceutical scientist explains why some medications are swallowed while others are injected What is fentanyl and why is it behind the deadly surge in US drug overdoses? A medical toxicologist explains Sepsis is one of the most expensive medical conditions in the world – new research clarifies how it can lead to cell death Rebecca Seal receives funding from National Institutes of Health Benedict Alter receives funding from National Institutes of Health, Foundation for Anesthesia Education and Research, and the International Anesthesia Research Society.
